Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals

Eradication of the hepatitis C virus (HCV) with interferon-free therapies (DAAs) has modified the course of the disease, as the rate of patients with compensated cirrhosis who achieve a sustained virological response exceeds 95%. However, the impact on development of hepatocellular carcinoma (HCC) i...

Full description

Saved in:
Bibliographic Details
Published inGastroenterología y hepatología Vol. 42; no. 8; p. 502
Main Authors Hernáez-Alsina, Tania, Caballol-Oliva, Berta, Díaz-González, Álvaro, Guedes-Leal, Cassia, Reig, María
Format Journal Article
LanguageEnglish
Spanish
Published Spain 01.10.2019
Subjects
Antiviral Agents - administration & dosage
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Carcinoma, Hepatocellular - etiology
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - therapy
Carcinoma, Hepatocellular - virology
Disease Progression
Embolization, Therapeutic
Hepatectomy
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Humans
Interferons
Liver Neoplasms - etiology
Liver Neoplasms - pathology
Liver Neoplasms - therapy
Liver Neoplasms - virology
Neoplasm Recurrence, Local - epidemiology
Neoplasm Recurrence, Local - etiology
Neoplasm Recurrence, Local - prevention & control
Prospective Studies
Retrospective Studies
VHC
Recurrence
Recurrencia
AAD
Carcinoma hepatocelular
DAA
Interferon-free
Hepatocellular carcinoma
Libre interferón
HCV
Online AccessGet more information

Cover

More Information
Summary:Eradication of the hepatitis C virus (HCV) with interferon-free therapies (DAAs) has modified the course of the disease, as the rate of patients with compensated cirrhosis who achieve a sustained virological response exceeds 95%. However, the impact on development of hepatocellular carcinoma (HCC) is currently in dispute. This argument could be divided into different key points: the impact of DAA on rate of HCC recurrence, the temporal link between starting DAAs and HCC recurrence, and finally, the aggressive pattern of HCC. Therefore, the aim of this review is to analyse the available results in this population of patients from a clinical perspective where the risks and benefits of HCV eradication with DAA therapies are evaluated in patients with complete response of HCC.
ISSN:0210-5705
DOI:10.1016/j.gastrohep.2019.05.003